Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2015 Nov 12

PMID 26554772

Citations 10

Authors

Beom Su Kim

Young Soo Park

Jeong Hwan Yook

Sung Tae Oh

Byung-Sik Kim

Affiliations

Soon will be listed here.

Abstract

The aim of this study is to test the prognostic accuracy of the 2010-WHO classification for postsurgery survival in nonmetastatic gastric neuroendocrine tumor (NET) cases. Whether the 2010-WHO classification of NETs can predict relapse after surgical resection has not yet been established.We selected 175 nonmetastatic gastric NET patients at Asan Medical Center, Seoul, Korea between 1996 and 2013. All tumors were classified using the WHO-2010 scheme.Among 175 patients with gastric NETs, we diagnosed 39 cases as WHO grade 1, 13 cases as grade 2, 66 cases as grade 3 (neuroendocrine carcinomas; NECs), and 57 cases as mixed with adenocarcinoma. Patients with grade 3 had a lower relapse-free survival (RFS) and overall survival (OS) than those with WHO grade 1/2 and had a lower OS than patients with mixed type tumors. Patients with grade 1/2 had a better OS than patients with mixed type. There was no significant difference in RFS and OS between small and large cell type lesions. Among WHO grade 1/2 patients with ≤1 cm sized lesions, none exhibited lympho-vascular, perineural, mucosal, or submucosal invasion, and we detected no lymph node metastases or recurrences.Our findings strongly suggest that WHO grade 3 behaves more aggressively than adenocarcinoma. Additionally, the survival of cases with large and small cell NEC was similar. Among WHO grade 1/2 patients who had ≤1 cm lesions, none exhibited lympho-vascular, perineural, mucosal, or submucosal invasion and all could be treated by endoscopic resection or minimally invasive surgery without node dissection.

Citing Articles

Bouveret Syndrome simultaneous with an incidental solitary Gastric Neuroendocrine Tumor in a 44-year-old female - A Case Report.

Shaheen J, Al Laham O, Ibrahim Basha Z, Atia F, Sharaf Aldeen R, Isaac M Ann Med Surg (Lond). 2023; 85(4):1206-1212.

PMID: 37113963 PMC: 10129185. DOI: 10.1097/MS9.0000000000000459.

Gastric neuroendocrine neoplasms: A review.

Koseoglu H, Duzenli T, Sezikli M World J Clin Cases. 2021; 9(27):7973-7985.

PMID: 34621854 PMC: 8462212. DOI: 10.12998/wjcc.v9.i27.7973.

Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors.

Sivandzadeh G, Ejtehadi F, Shoaee S, Aminlari L, Niknam R, Taghavi A BMC Gastroenterol. 2021; 21(1):238.

PMID: 34030644 PMC: 8142474. DOI: 10.1186/s12876-021-01821-6.

Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience.

Karakas Y, Lacin S, Kurtulan O, Esin E, Sunar V, Sokmensuer C Turk J Gastroenterol. 2020; 31(2):91-98.

PMID: 32141816 PMC: 7062132. DOI: 10.5152/tjg.2020.18919.

Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs.

Chen L, Zhou L, Zhang M, Shang L, Zhang P, Wang W BMC Cancer. 2017; 17(1):521.

PMID: 28778195 PMC: 5543548. DOI: 10.1186/s12885-017-3490-3.

References

Norton J, Melcher M, Gibril F, Jensen R . Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2005; 136(6):1267-74. DOI: 10.1016/j.surg.2004.06.057. View

Clark O, Benson 3rd A, Berlin J, Choti M, Doherty G, Engstrom P . NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009; 7(7):712-47. DOI: 10.6004/jnccn.2009.0050. View

Bordi C, Falchetti A, Azzoni C, DAdda T, Canavese G, Guariglia A . Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol. 1997; 21(9):1075-82. DOI: 10.1097/00000478-199709000-00012. View

Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol A, Nilsson O . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2008; 90(2):162-6. DOI: 10.1159/000182196. View

Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T . ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012; 95(2):157-76. DOI: 10.1159/000335597. View

Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B . Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008; 14(23):7798-803. DOI: 10.1158/1078-0432.CCR-08-0734. View

Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder W . TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449(4):395-401. PMC: 1888719. DOI: 10.1007/s00428-006-0250-1. View

Rappel S, Altendorf-Hofmann A, Stolte M . Prognosis of gastric carcinoid tumours. Digestion. 1995; 56(6):455-62. DOI: 10.1159/000201276. View

Pape U, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich S . Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008; 113(2):256-65. DOI: 10.1002/cncr.23549. View

10.

Endo S, Dousei T, Yoshikawa Y, Hatanaka N, Taniyama K, Yamauchi A . Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification. Int Surg. 2013; 97(4):335-9. PMC: 3727259. DOI: 10.9738/CC134.1. View

11.

Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R . Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010; 23(6):824-33. DOI: 10.1038/modpathol.2010.58. View

12.

Burkitt M, Pritchard D . Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006; 24(9):1305-20. DOI: 10.1111/j.1365-2036.2006.03130.x. View

13.

Godwin 2nd J . Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975; 36(2):560-9. DOI: 10.1002/1097-0142(197508)36:2<560::aid-cncr2820360235>3.0.co;2-4. View

14.

Kulke M, Anthony L, Bushnell D, de Herder W, Goldsmith S, Klimstra D . NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010; 39(6):735-52. PMC: 3100728. DOI: 10.1097/MPA.0b013e3181ebb168. View

15.

Strosberg J, Coppola D, Klimstra D, Phan A, Kulke M, Wiseman G . The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010; 39(6):799-800. PMC: 3100733. DOI: 10.1097/MPA.0b013e3181ebb56f. View

16.

Dolcetta-Capuzzo A, Villa V, Albarello L, Franchi G, Gemma M, Scavini M . Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer. 2012; 119(1):36-44. DOI: 10.1002/cncr.27716. View

17.

Modlin I, Lye K, Kidd M . A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4):934-59. DOI: 10.1002/cncr.11105. View

18.

La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A . Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2008; 40(1):30-40. DOI: 10.1016/j.humpath.2008.06.005. View

19.

Modlin I, Lye K, Kidd M . A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?. Am J Gastroenterol. 2003; 99(1):23-32. DOI: 10.1046/j.1572-0241.2003.04027.x. View

20.

Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes J . TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007; 451(4):757-62. DOI: 10.1007/s00428-007-0452-1. View